OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	30
Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study	27
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	22
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	21
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	19
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	18
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	16
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread	16
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	15
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	15
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	14
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	14
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	14
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	12
Brain metastases during follow-up of patients with resected cutaneous melanoma	12
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	12
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	11
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	10
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	10
Immunotherapy-induced granulomatous reaction in patients with melanoma	10
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	10
Ultraviolet A radiation exposure and melanoma: a review	9
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	9
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	9
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	9

Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	8
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	8
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	8
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	8
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	8
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	8
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma	8
Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?	8
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	7
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study	7
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma	7
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors	7
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	7
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	6
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	6
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study	6
Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors	6
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	6
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	6
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	6
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	6
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	6
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	5
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	5
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	5
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	5
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	5
Simultaneous melanomas in the setting of multiple primary melanomas	5
Melanoma risk during immunomodulating treatment	5
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	5
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials	5
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	5
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	5
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	5
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	5
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	5
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	5
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	5
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	5
Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to	5
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	5
Molecular profiling of primary uveal melanoma: results of a Polish cohort	4
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	4
Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models	4
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	4
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site	4
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	4
Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas	4